Condition: Pulmonary Arterial Hypertension (PAH) · Comorbidities · Cardiovascular Disease (CVD) · Sponsor: Assistance Publique - Hôpitaux de Paris
Pulmonary arterial hypertension (PAH) is a rare, progressive disease associated with poor prognosis, especially in patients with cardiovascular comorbidities. Current guidelines recommend initial combination therapy, but evidence is lacking for patients with significant comorbidities who are often excluded from clinical trials. The COMMODITIES trial is a multicenter, randomized, controlled study designed to compare the efficacy and safety of initial dual oral combination therapy (tadalafil and ambrisentan) versus oral monotherapy in newly diagnosed PAH patients with at least two cardiovascular comorbidities. The study aims to provide robust evidence to guide treatment strategies in this high-risk population.
This description comes directly from the study's public registry record.
Laurent SAVALE,, MD, PhD · +33 1 45 21 79 08 · laurent.savale@aphp.fr
Always discuss trial participation with your own doctor first.
| Hôpital Bicêtre -Service de pneumologie et soins intensifs respiratoires | Le Kremlin-Bicêtre, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07245680